Pharmacological agents such as SGLT2 inhibitors and GLP1 agonists have shown some promising results in weight reduction and cardiovascular protection in individuals with type 2 diabetes,69, 70 but the viability of these interventions at the population level remains unclear. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.